Highlights of This Issue 4417

SPECIAL FEATURES

CCR Translations

4419 TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal
Ramaswamy Govindan and Jason Weber
See related article, p. 4647

4422 "Companion Diagnostics": Has Their Time Come and Gone?
Fred R. Hirsch, Paul A. Bunn Jr, and Roy S. Herbst
See related article, p. 4488

CCR New Strategies

4425 New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Juliane M. Jürgensmeier, Joseph P. Eder, and Roy S. Herbst

CCR Perspectives in Drug Approval

4436 FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Laleh Amiri-Kordestani, Gideon M. Blumenthal, Qiang Casey Xu, Lijun Zhang, Shenghui W. Tang, Linan Ha, Wendy C. Weinberg, Bo Chi, Reyes Candau-Chao, Patricia Hughes, Anne M. Russell, Sarah Pope Miksinski, Xiao Hong Chen, W. David McGuinn, Todd Palmby, Sarah Friese-Hamim, Stepahnie Renua, Jean-Francois Dufour-Lamartine, Reza Elaidi, Celine Lerest, and Stephane Oudard

Molecular Pathways

4442 Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Felix Y. Feng, J. Chad Brenner, Maha Hussain, and Arul M. Chinnaiyan

CANCER THERAPY: CLINICAL

4449 Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

4459 p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Nicola R. Hardwick, Mary Carroll, Teodora Kaltcheva, Dajun Qian, Dean Lim, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espenschied, Joshua D.L. Ellenborn, Don J. Diamond, and Vincent Chung

4471 Phase I Safety and Pharmacodynamic of Inecalitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
Jacques Medioni, Gail Deplanque, Jean-Marc Ferrero, Tristan Maurina, Jean-Michel P. Rodier, Eric Raymond, Jorge Allyon, Gerard Maruani, Pascal Houiller, Sarah Mackenzie, Stephanie Renua, Jean-Francois Dufour-Lamartine, Reza Elaidi, Celine Lerest, and Stephane Oudard

PERSONALIZED MEDICINE AND IMAGING

4478 Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer
Christiane Amendt, Eike Staub, Manja Friese-Hamim, Stephan Störlkel, and Christoph Stroh

4488 Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
See related commentary, p. 4422
4499 A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
Zenia Saridaki, Joanne B. Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Rook, David W. Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, and Sabine Teijpar

4511 FcyRIIa and FcγRIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease
Francesco Sclafani, David Gonzalez de Castro, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Jaime Capdevila, Bengt Glimelius, Susana Roselló Keränen, Andrew Wotherspoon, Jean-Pierre Bourquin, Peter J. Houghton, Malcolm A. Smith, and Richard B. Lock

4520 Cell and Molecular Determinants of In Vitro Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts

4532 Noninvasive Detection of Glutamate Predicts Survival in Pediatric Medulloblastoma
Martin Wilson, Simrandip K. Gill, Lesley MacPherson, Martin English, Theodoros N. Arvanitis, and Andrew C. Peet

4540 Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH

4549 The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
Alison Backen, Andrew C. Renchen, Andrew R. Clamp, Carlo Berzunzi, Cong Zhou, Amit Oza, Selina Bannoo, Stefan J. Scherer, Rosamonde E. Banks, Caroline Dive, and Gordon C. Jayson

CANCER THERAPY: PRECLINICAL

4559 Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer
Zhe Zhang, Jiping Wang, Dongmei Ji, Chenchen Wang, Ruijiao Liu, Zheng Wu, Lian Liu, Dan Zhu, Jinjia Chang, Ruiruan Geng, Lei Xiong, Qiangyi Fang, and Jin Li

4574 SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Skalskaya, Victor S. Golubchik, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Marielle Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, and Véronique Blanc

4584 Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth
Savita Sankar, Emily R. Theisen, Jared Bearss, Timothy Mulvihill, Laura M. Hoffman, Venkatasureswamy Soma, Mary C. Beckerle, Sunil Sharma, and Stephen L. Lessnick

BIOLOGY OF HUMAN TUMORS

4598 Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis
Zhaojun Liu, Jia Zhang, Yanhong Gao, Lirong Pei, Jing Zhou, Liankun Gu, Lianhai Zhang, Budong Zhu, Naoko Hattori, Jiafu Ji, Yasuhito Yuasa, Wooho Kim, Toshikazu Ushijima, Huidong Shi, and Dajun Deng

4613 Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002
Sébastien Couraud, Felipe Vaca-Paniagua, Stéphanie Villar, Javier Oliver, Tibor Schuster, Hélène Blanché, Nicolas Girard, Jean Trédaniel, Laurent Guilleminault, Radv Gervais, Nathalie Prim, Michel Vincent, Jacques Margery, Sébastien Larivé, Pascal Foucher, Bernard Duvert, Maxime Vallée, Florence Le Calvez-Kelm, James McKay, Pascale Missy, Franck Morin, Gérard Zalcman, Magali Olivier, and Pierre-Jean Souquet for the BioCAST/IFCT-1002 investigators
Expression of Androgen and Estrogen Signaling Components and Stem Cell Markers to Predict Cancer Progression and Cancer-Specific Survival in Patients with Metastatic Prostate Cancer

Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Kenichi Takayama, Toru Sugihara, Daisuke Obinata, Yuta Yamada, Jimpei Kumagai, Haruki Kume, Yasuyoshi Ouchi, Satoshi Inoue, and Yukio Homma

miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer


Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Miguel A. Molina-Vila, Jordi Bertran-Alamillo, Amaya Gascó, Clara Mayo-de-las-Casas, María Sánchez-Ronco, Laia Pujantell-Pastor, Laura Bonanno, Adolfo G. Favaretto, Andrés F. Cardona, Alain Vergnenegre, Margarita Majem, Bartomeu Massuti, Teresa Morán, Enric Carcereny, Santiago Viteri, and Rafael Rosell

An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer


To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN

Daniel J. Shiwasrki, Chunbo Shao, Anke Bill, Jean Kim, Dong Xiao, Carol A. Bertrand, Raja S. Seethala, Daisuke Sano, Jeffery N. Myers, Patrick Ha, Jennifer Grandis, L. Alex Gaither, Manojkumar A. Puthenveedu, and Umamaheswar Duvvuri

TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome

Tiantian Sun, Wan Du, Hua Xiong, Yanan Yu, Yurong Weng, Linlin Ren, Huijun Zhao, Yingchao Wang, Yingxuan Chen, Jie Xu, Yongbing Xiang, Wenxin Qin, Weibiao Cao, Weiping Zou, Haoyan Chen, Jie Hong, and Jing-Yuan Fang

Decreased Expression of miR216a Contributes to Non–Small-Cell Lung Cancer Progression

Ren-Tao Wang, Meng Xu, Cheng-Xiong Xu, Zhi-Gang Song, and Hua Jin

GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion

Hong Zhang, Wei Hou, Hua-Li Wang, Hai-Jing Liu, Xin-Ying Jia, Xing-Zheng Zheng, Yong-Xin Zou, Xin Li, Lin Hou, Michael A. McNutt, and Bo Zhang
ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53 Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.
Clinical Cancer Research

20 (17)


Updated version  Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/17

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.